Assess the safety and efficacy of amitriptyline, pregabalin, and gabapentin for the management of neuropathic pain at Ayaan Institute of Medical Sciences

Abstract

Background: The most prevalent neuropathic pain disorders now being treated with tricyclic antidepressants (TCA), gabapentin, and pregabalin are considered first-line treatments for neuropathic pain. Many times, current neuropathic pain treatments are ineffective. Despite the availability of substantial information from numerous recommendations, there is still a significant degree of heterogeneity in treatment patterns. According to recent statistics from the Indian market, the guidelines actually advocate the use (selling) of medications including amitriptyline, pregabalin, and gabapentin.
Methods: This is a single-center, three-arm, prospective, comparative, open-label study conducted at Ayaan Institute of Medical Sciences and Research Center. X-rays, MRIs, and clinical examinations of the lumbosacral spine were used to diagnose 270 individuals with persistent lumbar radiculopathy. The patients were randomly assigned to three groups and given various treatments. Patients in Group A received 300 mg of gabapentine, patients in Group B received 75 mg of pregabaline, and patients in Group C received 10 mg of amitriptyline. Patients' global perception of change scale was used to gauge how much their overall condition had improved and how much pain they had relieved, as measured by a visual analogue scale. Every follow-up visit included a record of adverse medication responses.
Results: In three therapy groups, there was a notable improvement in pain alleviation for all patients. There were seventy patients overall in each group. Within Group A, there were 43 (61.4%) men and 28 (40%) women. Within Group B, there were 39 men (55.7%) and 31
women (44.28%). Within Group C, there were 41 men (58.5%) and 29 women (41.42%). The mean age of the patients in Group A was 53.21 ± 6.41 years. The mean age of the patients in group B was 55.14 ± 6.31 years. The mean age of the patients in group C was 56.31 ± 5.72. According to the p-value of 0.635, there was statistical non-significance.
Conclusions: In light of this, three groups have been demonstrated to be equally effective in reducing pain in NeP patients: amitriptyline, pregabaline, and gabapentine. Pregabalin has the same advantages as gabapentine and amitriptyline in terms of Numeric Pain Rating Scale (NPRS) scores.